Cardiac stem cell and myocyte secreted paracrine factors and uses thereof

Abstract

The invention relates to secreted proteins from cardiac stem cells (cardiospheres and cardiosphere-derived cells) or myocytes for diagnostic and/or therapeutic use

1 - 18 . (canceled) 
     
     
         19 . A method for screening a cardiac patient as a candidate for stem cell therapy, said method comprising measuring in a biological sample from the patient the amount of one or more of apolipoprotein E precursor, atriopeptigen (ANP, ANF), adrenomedullin, brain acid soluble protein 1 (BASP1 protein), cathepsin B precursor, collagen alpha-1 (VI) chain precursor, connective tissue growth factor, cystatin E/M, Dkk3 protein, insulin-like growth factor-binding protein 2 precursor, interleukin-1 receptor-like 1 precursor (ST2), matrix metallopeptidase 2, metalloproteinase inhibitor 1 precursor (TIMP-1), metalloproteinase inhibitor 2 precursor (TIMP-2), mimecan precursor, procollagen type III alpha 1, procollagen type V alpha 1, procollagen type 1 alpha 1, procollagen type VI alpha 2, tropoelastin, or peptide fragments thereof, compared to a baseline value, wherein a statistically significant amount of the one or more proteins or peptide fragments thereof compared to the baseline value indicates that the patient would be likely to benefit from stem cell therapy. 
     
     
         20 . The method of  claim 19 , wherein the statistically significant amount represents at least a 5% increase over baseline value. 
     
     
         21 . The method of  claim 19 , wherein the cardiac patient is suffering from angina, acute myocardial injury, cellular necrosis and myocardium hypertrophy or heart failure. 
     
     
         22 . The method of  claim 19 , wherein the biological sample is a whole blood sample, serum sample, plasma sample, tissue biopsy sample, a sample of cultured cells derived from tissue, or a sample of circulating stem cells such as EPC.